In the latest trading session, 0.45 million Jasper Therapeutics Inc (NASDAQ:JSPR) shares changed hands as the company’s beta touched 2.27. With the company’s most recent per share price at $6.42 changed hands at -$0.63 or -8.90% at last look, the market valuation stands at $96.34M. JSPR’s current price is a discount, trading about -383.02% off its 52-week high of $31.01. The share price had its 52-week low at $6.57, which suggests the last value was -2.34% down since then. When we look at Jasper Therapeutics Inc’s average trading volume, we note the 10-day average is 1.18 million shares, with the 3-month average coming to 424.69K.
Analysts gave the Jasper Therapeutics Inc (JSPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended JSPR as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Jasper Therapeutics Inc’s EPS for the current quarter is expected to be -1.26.
Jasper Therapeutics Inc (NASDAQ:JSPR) trade information
Instantly JSPR was in red as seen in intraday trades today. With action -66.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -69.96%, with the 5-day performance at -66.67% in the red. However, in the 30-day time frame, Jasper Therapeutics Inc (NASDAQ:JSPR) is -71.21% down. Looking at the short shares, we see there were 2.07 million shares sold at short interest cover period of 10.97 days.
The consensus price target for the stock as assigned by Wall Street analysts is 55.5, meaning bulls need an upside of 88.43% from its recent market value. According to analyst projections, JSPR’s forecast low is 48 with 63 as the target high. To hit the forecast high, the stock’s price needs a -881.31% plunge from its current level, while the stock would need to soar -647.66% for it to hit the projected low.
Jasper Therapeutics Inc (JSPR) estimates and forecasts
Data shows that the Jasper Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -66.38% over the past 6 months, a 27.51% in annual growth rate that is considerably higher than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Jasper Therapeutics Inc earnings to increase by 26.45%.
JSPR Dividends
Jasper Therapeutics Inc is expected to release its next quarterly earnings report in February.
Jasper Therapeutics Inc (NASDAQ:JSPR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.28% of Jasper Therapeutics Inc shares while 98.74% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.02%.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 401.22 shares estimated at $2.6 million under it, the former controlled 2.67% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.98% of the shares, roughly 296.68 shares worth around $1.92 million.
